FDA Nod For PBYI, ANIK Sees 23-26% Revenue Growth, CBAY Abuzz, RPRX Plunges

Today's Daily Dose brings you news about Anika's preliminary second quarter revenue; Asterias' progress in SCiStar trial; CymaBay's encouraging results from PBC trial; EDAP's Focal One update; Ligand's expanded license relationship with Amgen; Paratek's encouraging results from OASIS-2 study and FDA approval of Puma's breast cancer drug.

from RTT - Biotech http://ift.tt/2tAx9Fq
via IFTTT